Participants sought: Treatment for Behavioural Variant Fronto-temporal Dementia (bvFTD)

Imaging of Behavioral Variant Frontotemporal Dementia (bvFTD)
Image: © Bradford Dickerson

We are seeking participants with behavioural variant Fronto-temporal dementia (bvFTD) for our study.

This research project is looking at whether the trial drug, sodium selenate, decreases the rate of brain shrinkage in patients with bvFTD.

Participants are randomly assigned to one of two groups. One group will receive the study drug, sodium selenate, and the other group will receive a placebo.

Participation in this research involves attending appointments at the study doctor’s clinic up to ten times over 15 months, taking the study drug (or placebo) three times a day and maintaining a Diary Card (recording any side effects or medication changes).

The appointments will include MRI & PET scans, two lumbar punctures, physical & neurological examinations, blood tests, and cognitive tests & questionnaires.

We are currently recruiting participants with bvFTD to take part in this study across four sites, three in Melbourne and one in Sydney.

Enquiries

• Contact: Dr Lucy Vivash, Department of Neuroscience in Central Clinical School
• Email: selenate@alfred.org.au
• Phone: (03) 9903 0860
• Web: www.monash.edu/medicine/ccs/neuroscience/home
• Ethics Committee Project Number: Alfred 609/19